![Annette Clancy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Annette Clancy
Direttore/Membro del Consiglio presso
Abcd Ltd.
Profilo
Ms. Annette V.
Clancy is an Operating Partner at Jeito Capital SASU.
She is on the Board of Directors at Abcd Ltd. Ms. Clancy was previously employed as a Non-Executive Chairman by ENYO Pharma SA, an Independent Non-Executive Director by Lysogene SA, an Independent Director by Swedish Orphan Biovitrum AB, a Chairman by ObsEva SA, a Chairman by Genable Technologies Ltd., a Non-Executive Director by Aqualis ASA /Old/, a Non-Executive Director by Silence Therapeutics Plc, and a Head-Transactions & Alliance Management by GlaxoSmithKline Plc.
She received her undergraduate degree from the University of Bath.
Ultime notizie su Annette Clancy
Posizioni attive di Annette Clancy
| Società | Posizione | Inizio |
|---|---|---|
Abcd Ltd. | Direttore/Membro del Consiglio | - |
Jeito Capital SASU
 Jeito Capital SASU Investment ManagersFinance Jeito Capital is an active manager which seeks investment opportunities in companies located in Europe. The firm targets companies operating in the fields of biotech and biopharma. It provides financing for early stage capital requirements. | Investitore di Private Equity | 08/09/2026 |
Precedenti posizioni note di Annette Clancy
| Società | Posizione | Fine |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Presidente | 11/12/2024 |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Presidente | 01/12/2023 |
| OBSEVA SA | Presidente | 10/03/2023 |
| LYSOGENE | Presidente | 22/05/2019 |
Spark Therapeutics Ireland Ltd.
 Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Develops new gene medicines to treat autosomal dominant genetic diseases | Presidente | 01/03/2016 |
Formazione di Annette Clancy
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
80
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Bath
 University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Silence Therapeutics Plc
 Silence Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services Engages in the research and development of novel pharmaceutical products | Commercial Services |
Weifa ASA
 Weifa ASA Pharmaceuticals: MajorHealth Technology Manufactures non-prescription and over-the-counter pharmaceutical products | Health Technology |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Develops new gene medicines to treat autosomal dominant genetic diseases | Health Technology |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
ObsEva SA
 ObsEva SA Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments to increase women's reproductivity | Health Technology |
Lysogene SA
 Lysogene SA BiotechnologyHealth Technology Engages in research and clinical development of gene therapy for neurodegenerative disorders | Health Technology |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Abcd Ltd. | |
Jeito Capital SASU
Jeito Capital SASU Investment ManagersFinance Jeito Capital is an active manager which seeks investment opportunities in companies located in Europe. The firm targets companies operating in the fields of biotech and biopharma. It provides financing for early stage capital requirements. | Finance |
